{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:36:53Z","timestamp":1783593413030,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04179-x","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T10:47:41Z","timestamp":1739702861000},"page":"387-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews"],"prefix":"10.1007","volume":"88","author":[{"given":"Xiaoye","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"issue":"5","key":"4179_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.17269\/s41997-022-00636-6","volume":"113","author":"JW Frank","year":"2022","unstructured":"J.W. Frank, Controlling the obesity pandemic: Geoffrey rose revisited. Can. J. Public Health 113(5), 736\u2013742 (2022). https:\/\/doi.org\/10.17269\/s41997-022-00636-6","journal-title":"Can. J. Public Health"},{"issue":"1","key":"4179_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"A. Afshin, M.H. Forouzanfar, M.B. Reitsma et al. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med. 377(1), 13\u201327 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1614362","journal-title":"N. Engl. J. Med."},{"key":"4179_CR3","unstructured":"World Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"4179_CR4","doi-asserted-by":"publisher","unstructured":"L.J. Akinbami, T.C. Chen, O. Davy, et al. National health and nutrition examination survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines. Vital Health Stat. 1(190), 1\u201336 (2022). https:\/\/doi.org\/10.15620\/cdc:115434","DOI":"10.15620\/cdc:115434"},{"issue":"4","key":"4179_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.fertnstert.2017.02.104","volume":"107","author":"DR Meldrum","year":"2017","unstructured":"D.R. Meldrum, M.A. Morris, J.C. Gambone, Obesity pandemic: causes, consequences, and solutions-but do we have the will? Fertil. Steril. 107(4), 833\u2013839 (2017). https:\/\/doi.org\/10.1016\/j.fertnstert.2017.02.104","journal-title":"Fertil. Steril."},{"key":"4179_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"D.P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C.L. Birmingham, A.H. Anis, The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public. Health 9, 88 (2009). https:\/\/doi.org\/10.1186\/1471-2458-9-88","journal-title":"BMC Public. Health"},{"issue":"10031","key":"4179_CR7","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/s0140-6736(16)00271-3","volume":"387","author":"GA Bray","year":"2016","unstructured":"G.A. Bray, G. Fr\u00fchbeck, D.H. Ryan, J.P. Wilding, Management of obesity. Lancet 387(10031), 1947\u20131956 (2016). https:\/\/doi.org\/10.1016\/s0140-6736(16)00271-3","journal-title":"Lancet"},{"key":"4179_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/ppa.S103649","volume":"10","author":"M Lemstra","year":"2016","unstructured":"M. Lemstra, Y. Bird, C. Nwankwo, M. Rogers, J. Moraros, Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer. Adherence 10, 1547\u20131559 (2016). https:\/\/doi.org\/10.2147\/ppa.S103649","journal-title":"Patient Prefer. Adherence"},{"issue":"7","key":"4179_CR9","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009). https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med."},{"key":"4179_CR10","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"B.J. Shea, B.C. Reeves, G. Wells et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 358, j4008 (2017). https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"Bmj"},{"key":"4179_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"Bmj"},{"issue":"4","key":"4179_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"G. Guyatt, A.D. Oxman, E.A. Akl et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 64(4), 383\u2013394 (2011). https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J. Clin. Epidemiol."},{"issue":"10148","key":"4179_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"P.M. O\u2019Neil, A.L. Birkenfeld, B. McGowan et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392(10148), 637\u2013649 (2018). https:\/\/doi.org\/10.1016\/s0140-6736(18)31773-2","journal-title":"Lancet"},{"issue":"3","key":"4179_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"M. Friedrichsen, A. Breitschaft, S. Tadayon, A. Wizert, D. Skovgaard, The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes. Metab. 23(3), 754\u2013762 (2021). https:\/\/doi.org\/10.1111\/dom.14280","journal-title":"Diabetes Obes. Metab."},{"key":"4179_CR15","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.diabres.2021.108935","volume":"178","author":"M Jensterle","year":"2021","unstructured":"M. Jensterle, S. Ferjan, A. Vovk, T. Battelino, M. Rizzo, A. Jane\u017e, Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res. Clin. Pract. 178, 108935 (2021). https:\/\/doi.org\/10.1016\/j.diabres.2021.108935","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"14","key":"4179_CR16","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"D. Rubino, N. Abrahamsson, M. Davies et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama 325(14), 1414\u20131425 (2021). https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"Jama"},{"issue":"18","key":"4179_CR17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"M. Sodhi, R. Rezaeianzadeh, A. Kezouh, M. Etminan, Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Jama 330(18), 1795\u20131797 (2023). https:\/\/doi.org\/10.1001\/jama.2023.19574","journal-title":"Jama"},{"issue":"3","key":"4179_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/andr.13519","volume":"12","author":"G Lisco","year":"2024","unstructured":"G. Lisco, N. Bartolomeo, A. De Tullio et al. Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: a retrospective cohort study. Andrology 12(3), 633\u2013642 (2024). https:\/\/doi.org\/10.1111\/andr.13519","journal-title":"Andrology"},{"key":"4179_CR19","doi-asserted-by":"publisher","unstructured":"C. Able, B. Liao, G. Saffati, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int. J. Impot. Res. (2024). https:\/\/doi.org\/10.1038\/s41443-024-00895-6","DOI":"10.1038\/s41443-024-00895-6"},{"issue":"8","key":"4179_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"J.T. Hathaway, M.P. Shah, D.B. Hathaway et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 142(8), 732\u2013739 (2024). https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"4179_CR21","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","volume":"23","author":"J Iqbal","year":"2022","unstructured":"J. Iqbal, H.X. Wu, N. Hu et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes. Rev. 23(6), e13435 (2022). https:\/\/doi.org\/10.1111\/obr.13435","journal-title":"Obes. Rev."},{"issue":"7","key":"4179_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1055\/a-1844-1176","volume":"54","author":"X Guo","year":"2022","unstructured":"X. Guo, Z. Zhou, X. Lyu et al. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm. Metab. Res. 54(7), 458\u2013471 (2022). https:\/\/doi.org\/10.1055\/a-1844-1176","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"4179_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HC Tan","year":"2022","unstructured":"H.C. Tan, O.A. Dampil, M.M. Marquez, Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J. ASEAN Fed. Endocr. Soc. 37(2), 65\u201372 (2022). https:\/\/doi.org\/10.15605\/jafes.037.02.14","journal-title":"J. ASEAN Fed. Endocr. Soc."},{"issue":"4","key":"4179_CR24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s11096-022-01428-1","volume":"44","author":"N Arastu","year":"2022","unstructured":"N. Arastu, O. Cummins, W. Uribe, E.C. Nemec, Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. Int. J. Clin. Pharm. 44(4), 852\u2013859 (2022). https:\/\/doi.org\/10.1007\/s11096-022-01428-1","journal-title":"Int. J. Clin. Pharm."},{"issue":"3","key":"4179_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","volume":"75","author":"P Zhong","year":"2022","unstructured":"P. Zhong, H. Zeng, M. Huang, W. Fu, Z. Chen, Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine 75(3), 718\u2013724 (2022). https:\/\/doi.org\/10.1007\/s12020-021-02945-1","journal-title":"Endocrine"},{"key":"4179_CR26","doi-asserted-by":"publisher","first-page":"935823","DOI":"10.3389\/fphar.2022.935823","volume":"13","author":"X Gao","year":"2022","unstructured":"X. Gao, X. Hua, X. Wang et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 13, 935823 (2022). https:\/\/doi.org\/10.3389\/fphar.2022.935823","journal-title":"Front. Pharmacol."},{"issue":"3","key":"4179_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","volume":"26","author":"W Qin","year":"2024","unstructured":"W. Qin, J. Yang, C. Deng, Q. Ruan, K. Duan, Efficacy and safety of semaglutide 2.4\u2009mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diabetes, Obes. Metab. 26(3), 911\u2013923 (2024). https:\/\/doi.org\/10.1111\/dom.15386","journal-title":"Diabetes, Obes. Metab."},{"issue":"11","key":"4179_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"J.P.H. Wilding, R.L. Batterham, S. Calanna et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384(11), 989\u20131002 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"4179_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"T.A. Wadden, T.S. Bailey, L.K. Billings et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14), 1403\u20131413 (2021). https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA"},{"issue":"9","key":"4179_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"J. Blundell, G. Finlayson, M. Axelsen et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes. Metab. 19(9), 1242\u20131251 (2017). https:\/\/doi.org\/10.1111\/dom.12932","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4179_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"D.M. Rubino, F.L. Greenway, U. Khalid et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. Jama 327(2), 138\u2013150 (2022). https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"Jama"},{"issue":"3","key":"4179_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"J.B. Hjerpsted, A. Flint, A. Brooks, M.B. Axelsen, T. Kvist, J. Blundell, Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes. Metab. 20(3), 610\u2013619 (2018). https:\/\/doi.org\/10.1111\/dom.13120","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"4179_CR33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"W.T. Garvey, R.L. Batterham, M. Bhatta et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28(10), 2083\u20132091 (2022). https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04179-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:47:36Z","timestamp":1747036056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4179"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04179-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,16]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}